BR112017024783A2 - composições contraceptivas e métodos para eficácia melhorada e modulação dos efeitos colaterais - Google Patents

composições contraceptivas e métodos para eficácia melhorada e modulação dos efeitos colaterais

Info

Publication number
BR112017024783A2
BR112017024783A2 BR112017024783A BR112017024783A BR112017024783A2 BR 112017024783 A2 BR112017024783 A2 BR 112017024783A2 BR 112017024783 A BR112017024783 A BR 112017024783A BR 112017024783 A BR112017024783 A BR 112017024783A BR 112017024783 A2 BR112017024783 A2 BR 112017024783A2
Authority
BR
Brazil
Prior art keywords
methods
progestin
shbg
side effects
modulation
Prior art date
Application number
BR112017024783A
Other languages
English (en)
Portuguese (pt)
Inventor
Kydonieus Agis
Macfarlane Katie
E Kafrissen Michael
Original Assignee
Agile Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agile Therapeutics Inc filed Critical Agile Therapeutics Inc
Publication of BR112017024783A2 publication Critical patent/BR112017024783A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BR112017024783A 2015-05-18 2016-05-18 composições contraceptivas e métodos para eficácia melhorada e modulação dos efeitos colaterais BR112017024783A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562163113P 2015-05-18 2015-05-18
US201562254999P 2015-11-13 2015-11-13
PCT/US2016/033024 WO2016187269A1 (en) 2015-05-18 2016-05-18 Contraceptive compositions and methods for improved efficacy and modulation of side effects

Publications (1)

Publication Number Publication Date
BR112017024783A2 true BR112017024783A2 (pt) 2018-08-07

Family

ID=56116539

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017024783A BR112017024783A2 (pt) 2015-05-18 2016-05-18 composições contraceptivas e métodos para eficácia melhorada e modulação dos efeitos colaterais

Country Status (10)

Country Link
US (3) US20180125860A1 (https=)
EP (1) EP3297634A1 (https=)
JP (2) JP2018515552A (https=)
CN (1) CN107995864A (https=)
AU (2) AU2016264137B2 (https=)
BR (1) BR112017024783A2 (https=)
CA (1) CA2986039A1 (https=)
HK (1) HK1251938A1 (https=)
MX (1) MX2017014768A (https=)
WO (1) WO2016187269A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2383279A1 (en) 2011-07-19 2011-11-02 Pantarhei Bioscience B.V. Process for the preparation of estetrol
DK3701944T3 (da) 2015-06-18 2022-03-14 Estetra Srl Oro-dispergerbar doseringsenhed indeholdende en estetrolkomponent
LT3310346T (lt) 2015-06-18 2021-06-10 Estetra Sprl Burnoje disperguojama tabletė, turinti estetrolio
LT3310345T (lt) 2015-06-18 2021-06-25 Estetra Sprl Burnoje disperguojama tabletė, turinti estetrolio
CR20180042A (es) 2015-06-18 2018-05-03 Mithra Pharmaceuticals S A Unidad de dosificación orodispersable que contiene un componente estetrol.
KR102712911B1 (ko) 2016-08-05 2024-10-04 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 월경통 및 생리통의 관리방법
US20200129524A1 (en) * 2017-03-15 2020-04-30 Agile Therapeutics, Inc. Personalized contraceptive formulations
CN111989105B (zh) 2018-04-19 2024-07-19 埃斯特拉私人有限责任公司 化合物以及它们在缓解绝经相关症状中的用途
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
TWI893101B (zh) 2020-04-16 2025-08-11 比利時商埃斯特拉有限責任公司 具有降低之副作用之避孕組成物

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5208225A (en) * 1986-02-27 1993-05-04 Warner-Lambert Company Compositions containing fixed combinations
IE61236B1 (en) * 1986-07-15 1994-10-19 American Home Prod Combination dosage form for pre-menopausal women
US4863738A (en) 1987-11-23 1989-09-05 Alza Corporation Skin permeation enhancer compositions using glycerol monooleate
US5474783A (en) 1988-03-04 1995-12-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
MX9301121A (es) * 1992-03-02 1993-09-01 Schering Ag Metodo y equipo para la contracepcion oral y regulacion de la menstruacion con estrogeno/progestina/aniprogestina.
US7704983B1 (en) * 1992-03-02 2010-04-27 Eastern Virginia Medical School Antiprogestin method for reducing side effects associated with low dosage HRT and oral contraception
US5552394A (en) * 1994-07-22 1996-09-03 The Medical College Of Hampton Roads Low dose oral contraceptives with less breakthrough bleeding and sustained efficacy
CN1188189C (zh) 1995-06-07 2005-02-09 奥瑟－麦内尔制药公司 基质层含有17－脱乙酰基诺孕酯的经皮贴片及基质的用途
US6139873A (en) * 1996-07-10 2000-10-31 Cedars-Sinai Medical Center Combined pharmaceutical estrogen-androgen-progestin
US5898032A (en) * 1997-06-23 1999-04-27 Medical College Of Hampton Roads Ultra low dose oral contraceptives with less menstrual bleeding and sustained efficacy
US6251956B1 (en) * 1998-08-20 2001-06-26 Ortho Pharmaceutical Corporation Combination progestin oral contraceptive regimen
DE19739916C2 (de) * 1997-09-11 2001-09-13 Hesch Rolf Dieter Verwendung einer Kombination aus einem Gestagen und einem Estrogen zur kontinuierlichen Ovulationshemmung und ggf. gleichzeitigen Behandlung und/oder Prophylaxe von Tumoren der Brustdrüsen
US7384650B2 (en) * 1999-11-24 2008-06-10 Agile Therapeutics, Inc. Skin permeation enhancement composition for transdermal hormone delivery system
US7045145B1 (en) 1999-11-24 2006-05-16 Agile Therapeutics, Inc. Transdermal contraceptive delivery system and process
BR0015802B1 (pt) * 1999-11-24 2014-04-29 Agile Therapeutics Inc Sistema de administração de contraceptivo transdérmico, e, método para produzir um sistema de administração de contraceptivo transdérmico
ATE485837T1 (de) 2000-08-03 2010-11-15 Antares Pharma Ipl Ag Zusammensetzung zur transdermalen und/oder transmukosalen verabreichung von wirkstoffen, die ausreichende therapeutische spiegel garantiert
JP4965263B2 (ja) * 2003-12-12 2012-07-04 バイエル ファーマ アクチエンゲゼルシャフト 浸透増強剤を必要としないホルモンの経皮送達
CN1672685A (zh) * 2004-03-26 2005-09-28 董可娟 一种新的避孕药物
US20100178323A1 (en) * 2007-07-10 2010-07-15 Agis Kydonieus Dermal Delivery Device
CA2704117C (en) 2007-11-02 2015-11-17 Acrux Dds Pty Ltd Transdermal delivery system
ES2734510T3 (es) * 2008-10-08 2019-12-10 Agile Therapeutics Inc Administración transdérmica
CA2740004A1 (en) * 2008-10-08 2010-04-15 Agile Therapeutics, Inc. Transdermal delivery
US9198919B2 (en) * 2008-10-08 2015-12-01 Agile Therapeutics, Inc. Contraceptive transdermal delivery of hormones
EP2410859A4 (en) * 2009-03-27 2013-03-13 Agile Therapeutics Inc TRANSDERMAL ADMINISTRATION
EP2806862A2 (en) 2012-01-27 2014-12-03 Agile Therapeutics, Inc. Transdermal hormone delivery
EA030797B1 (ru) * 2012-12-21 2018-09-28 ТЕЙКОКУ ФАРМА ЮЭсЭй, ИНК. Система трансдермальной доставки гормонов (варианты) и способы ее применения

Also Published As

Publication number Publication date
HK1251938A1 (zh) 2019-05-03
US20240156838A1 (en) 2024-05-16
AU2021262853B2 (en) 2024-05-09
CN107995864A (zh) 2018-05-04
CA2986039A1 (en) 2016-11-24
JP2021169503A (ja) 2021-10-28
US20250319102A1 (en) 2025-10-16
AU2021262853A1 (en) 2021-12-02
EP3297634A1 (en) 2018-03-28
AU2016264137B2 (en) 2021-08-19
JP2018515552A (ja) 2018-06-14
WO2016187269A1 (en) 2016-11-24
MX2017014768A (es) 2018-03-23
AU2016264137A1 (en) 2018-01-18
US20180125860A1 (en) 2018-05-10

Similar Documents

Publication Publication Date Title
BR112017024783A2 (pt) composições contraceptivas e métodos para eficácia melhorada e modulação dos efeitos colaterais
CL2020002024A1 (es) Moduladores de calpaínas y usos terapeuticos de los mismos. (divisional solicitud 201900793)
MX2021005350A (es) Compuestos de piridazinona y usos de los mismos.
BR112015018087A8 (pt) composto, composição farmacêutica e uso
MY190855A (en) Glucagon derivative, conjugate thereof, composition comprising same and therapeutic use thereof
CL2017003436A1 (es) Compuestos de benzoxacepina oxazolidinona y métodos de uso
MX386413B (es) Combinaciones terapéuticas que comprenden un inhibidor de raf y un inhibidor de erk.
WO2017100700A3 (en) Peptides for renal therapy
CR20190433A (es) Compuestos de pirimidinil-pyridiloxi-naftil y métodos para tratar enfermedades y trastornos relacionados con ire1
ZA202006377B (en) Boronic acid derivatives and therapeutic uses thereof
BR112015023391A2 (pt) formulações compreendendo conjugado droga-anticorpo anti-egfr
ZA201902051B (en) Pharmaceutical composition
MX388786B (es) Moduladores nmda espiro-lactam y métodos de uso de los mismos.
CA3030422C (en) Stabilizing excipients for therapeutic protein formulations
BR112015017246A2 (pt) formulação farmacêutica que compreende um corticosteroide insolúvel e um corticosteroide solúvel
SA521421715B1 (ar) تركيبات سيماجلوتيد ثابتة واستخداماتها
MX2021010022A (es) Composicion farmaceutica.
NI201700173A (es) Anticonceptivos a base de drospirenona para paciente femenina afectada con exceso de peso
MX2021006969A (es) Ligante peptidico.
BR112016001544A8 (pt) composições farmacêuticas para a administração intraocular que compreende um agente antibacteriano e um agente anti-inflamatório
NZ786543A (en) Compounds active towards nuclear receptors
BR112016005252A2 (pt) composto direcionado às proteínas poliposi coli adematosa (apc) truncadas, uso do mesmo e célula epitelial do cólon humana imortalizada (hcec)
MX391152B (es) Formulaciones farmaceuticas que comprenden cangrelor de alta pureza y metodos para preparar y utilizar las mismas.
EP3760195A4 (en) COMPOSITION WITH 2,3-BUTANEDIOL AS THE ACTIVE SUBSTANCE
MX2020007293A (es) Compuestos desuterados, composiciones y metodos para tratar canceres asociados con la activacion etbr.

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]